Cognitive, Behavioral and Aging Effects of Pain Medication in Alcohol Users



Status:Recruiting
Conditions:Psychiatric
Therapuetic Areas:Psychiatry / Psychology
Healthy:No
Age Range:35 - Any
Updated:11/19/2017
Start Date:November 2015
End Date:April 2019
Contact:Reba Blissel, B.S.
Email:caap@uw.edu
Phone:206.616.3075

Use our guide to learn which trials are right for you!

The purpose of this study is to examine the relationship between heavy alcohol use, pain, and
response to pain medication in older adults.

Potential participants complete a phone screen. If still found eligible, the participant
comes in for 1 screening visit (3 hours long). Cognitive/problem solving tests, computerized
tasks, CPT, questionnaires and functional measures are administered along with a screening
blood lab. If a participant is eligible, he/she comes back for 1 full study day visit (9-10
hours long). A testing battery (similar to the one done during the screening visit) is
completed at baseline and again at three timepoints following medication administration.
Blood draws, vital signs, and pupil measurements are taken throughout the day. A follow-up
phone call is completed within a few days of the full study day visit, during which a
questionnaire is given.

Inclusion Criteria:

- Age of 35 years old or above

- Mild to moderate pain

- alcohol consumption

- willingness to refrain from taking any sort of pain medication 24 hours prior to study
visit as well as refraining from taking sedative-hypnotics, antihistamines,
benzodiazepines, sleep aids, NSAIDs/opioid pain medications, alcohol, marijuana

- Cigarette smokers must be willing to refrain from smoking during the all day study
visit

Exclusion Criteria:

- current regular use of an opioid or medications that involve the opioid receptor
(naltrexone (vivitrol), buprenorphine (subutex), methadone (dolophine)

- abstains from alcohol

- unstable angina or CHF; cerebral vascular accident or recurrent TIAs in the prior 6
months, active cancer requiring current treatment, possible or probable dementia or
mild cognitive impairment

- Diagnosis of schizophrenia or schizoaffective disorder, or anxiety disorder requiring
regular medication

- History of recreational drug use in the past 1 year, excluding marijuana

- New or increased dose (within last 6 months) of CNS-active medications that may alter
neurocognitive and/or psychomotor function: MAO inhibitors, neuroleptics,
antidepressants, anticonvulsants, benzodiazepines, sleep aids

- Medications that may alter oxycodone metabolism: St. John's wort, Dilantin, tegretol,
corticosteroids, rifampin

- Known hypersensitivity to oxycodone and other opioids;

- Pregnancy
We found this trial at
1
site
1959 NE Pacific St
Seattle, Washington 98195
(206) 598-3300
Principal Investigator: Monique M. Cherrier, Ph.D.
Phone: 206-616-3075
University of Washington Medical Center University of Washington Medical Center is one of the nation's...
?
mi
from
Seattle, WA
Click here to add this to my saved trials